COVID-19 Diagnostics MarketPosted by NISHA SHAHA on May 9th, 2022 The global COVID-19 diagnostics market accounted for US$ 4.9 billion in 2020 and is estimated to be US$ 8.3 billion by 2029 and is anticipated to register a CAGR of 6.1%. The report \"Global COVID-19 Diagnostics Market, By Product (Instruments and Reagents & Kits), By Sample Type (Oropharyngeal & Nasopharyngeal Swabs, Blood, Urine, and Others), By Technology (Polymerase Chain Reaction (PCR), Antibody or Enzyme-Linked Immunosorbent Assay (ELISA), Serology, Portable or Point-of-Care (POC), and Others), By End-user (Laboratories, Hospitals, Diagnostic Centers & Clinics, and Research Institutes), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2027”. Key Highlights:
Analyst View: Growth in prevalence’s of coronavirus worldwide Due to increasing number of cases infected by coronavirus globally, there is increase in need for developing diagnostic tests which is expected to propel the global market growth. In addition, for accurate and efficient COVID-19 diagnosis, clinicians requires an on-site or a portable diagnostic test for real-time management of patients in minimal time. This has led to stimulate the approval of Point-of-Care (POC) testing for diagnosis, mainly designed at decreasing the assay duration from hours to a few minutes. For instance, in March 2020, the Food and Drug Administration (FDA) delivered Emergency Use Authorization (EUA) to the first POC test-Xpert Xpress test developed by Cepheid-for COVID-19 diagnosis. Chembio and Abbott Diagnostics are among the leading market players working in the point-of-care marketplace. Integration of novel technologies Adoption of software solutions and novel technologies with COVID-19 testing is projected to create new avenues for market expansion. For example, the manufactures are involved in incorporating artificial intelligence (AI) algorithms in COVID-19 tests for efficient and rapid diagnosis. Moreover, Surgisphere Corporation, a U.S.-based firm, launched an AI-based rapid diagnostic tool for the detection of coronavirus in March 2020. This diagnostic tool involves 99.9% specificity and 93.7% sensitivity, supplementing accurate identification of virus and avoiding transmission of the infection. Key Market Insights from the report: The global COVID-19 diagnostics market accounted for US$ 4.9 billion in 2020 and is estimated to be US$ 8.3 billion by 2029 and is anticipated to register a CAGR of 6.1%. The market report has been segmented on the basis of product, sample type, technology, end-user, and region.
To know the upcoming trends and insights prevalent in this market, click the link below: https://www.prophecymarketinsights.com/market_insight/Global-COVID-19-Diagnostics-Market-4255 Competitive Landscape: The prominent player operating in the global COVID-19 diagnostics market includes Abbott Diagnostics, Accelerate Diagnostics, Expedeon Ltd., Beckman Coulter Inc., Ador Diagnostics, Cepheid Inc., Akonni Biosystems Inc., Bio-Rad Laboratories, Becton, Dickinson and Company, Lonza, and Fusion Genomics Corporation. Related Reports: https://prophecymarketinsights.blogspot.com/2022/05/bone-graft-substitutes-market-is.html
To know more Contact Us: Sales Prophecy Market Insights Like it? Share it!More by this author |